Vertex Pharmaceuticals announces FDA clearance of VX-407 IND

Vertex Pharmaceuticals announced that the FDA has cleared the investigational new drug application, or IND, for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease in patients with a subset of PKD1 genetic variants. ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease.